Drug Profile
AHA 008
Latest Information Update: 22 Feb 2001
Price :
$50
*
At a glance
- Originator Medivir AB
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 22 Feb 2001 No-Development-Reported for HIV infections treatment in Sweden (Unknown route)
- 20 May 1998 Preclinical development for HIV infections treatment in Sweden (Unknown route)